Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.

Winnie YeoTakayuki UenoChing-Hung LinQiang LiuKyung-Hun LeeRoland LeungYoichi NaitoYeon Hee ParkSeock-Ah ImHuiping LiYoon Sim YapYen-Shen Lunull null

Published in: Breast cancer research and treatment (2019)

Premenopausal Asian women with breast cancer have unique disease characteristics and may benefit from treatment that differs somewhat from international guidelines. Given the great diversity of patients and clinical settings worldwide, the ABCCG advocates evidence-based yet flexible and individualized use of all potential options to improve breast cancer outcomes.

Keyphrases

breast cancer risk
end stage renal disease
postmenopausal women
ejection fraction
chronic kidney disease
newly diagnosed
clinical practice
polycystic ovary syndrome
type diabetes
risk assessment
insulin resistance
metabolic syndrome
skeletal muscle
patient reported outcomes
early breast cancer